SSEV, TTEG, MCET, IMJX, PWRM, HTDS OTCPicks.com Stocks to Watch for Tuesday, August 25th

Our Stocks to Watch tomorrow include Systems Evolution Inc. (OTC: SSEV), Turbine Truck Engines Inc. (OTCBB: TTEG), MultiCell Technologies Inc. (OTCBB: MCET), ImageXpres Corp. (OTC: IMJX), Power3 Medical Products Inc. (OTCBB: PWRM) and Hard to Treat Diseases Inc. (OTC: HTDS).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

SYSTEMS EVOLUTION INCORPORATED (OTC: SSEV)

"Up 380.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/SSEV.php 

Systems Evolution, Inc. (SEVI), a professional services organization, provides computer software development services, computer network support, and contract staff for its clients. The company uses Microsoft and IBM Rational tools to build software and support computer networks. The company’s principal client is the State of Texas government. The company, through its subsidiary, Southwest CMS Technology Services LP and its general partner CMS Associates, LLC (CMS), provides Microsoft and Novell network integration. SEVI operates Next Hire Consultants, Inc. (Next Hire), Houston based staffing firm providing placement services to the infrastructure engineering industry. SEVI’s subsidiaries also include Duration Software, Inc. (Duration), a software development company based in Austin that provided services primarily to State of Texas departments. SERVICES The company had two distinct divisions — the Consulting Division that provides software development and managed network support services, and the Next Hire Consultants Division (NHC) that provides engineering permanent placement services. Consulting Division The company’s consulting division provides software development services using Microsoft .Net and the IBM Rational Unified Process. ‘.NET’ is the Microsoft Web services strategy integrated across the Microsoft platform, whose technology provides the ability to build, deploy, manage, and use connected, security-enhanced solutions with Web services. The IBM Rational Unified Process is an IBM copyrighted process for delivering software development services, using a software engineering implementation framework. The company’s consulting division also provides managed network support services from its network operations center in San Antonio. The company’s managed network support services provide proactive management of network servers and workstations, including application of operating system patches, analysis of available resources, analysis of hardware viability, firewall maintenance, help desk support services, and uptime service level agreements (SLA). Markets and Clients: The company, through its consulting division primarily offers its services in Houston, San Antonio, and Austin. The consulting division’s principal clients are the State of Texas and MedDorna. NHC Division The company’s NHC division provides permanent placement services, with a focus on placement of engineers in the oil & gas and public infrastructure industries. NHC offers, a managed recruiting service that provides ongoing recruiting support for its clients’ internal Human Resource departments. This service provides NHC recruiting professionals and segregated access to the company’s internal candidate database for each client. Markets and Clients: The company, through its NHC division primarily offers its services in SEVI’s Houston office. NHC’s principal clients are Staffing Technologies and Shell Oil USA, Inc. Vendor Partner Programs The company’s third party vendor partners include Microsoft and IBM Rational, each have annual partnership agreements that require vendor certified employees and partner license usage. Competition The company’s principal competitors include: regional consulting firms, such as Perficient Inc. and eLinear Solutions; national consulting firms, such as Answerthink, Inc., Accenture, BearingPoint, Inc., Ciber, Inc., Electronic Data Systems Corporation, and Sapient Corporation; and offshore providers, such as Cognizant Technology Solutions Corporation, Infosys Technologies Limited, Satyam Computer Services Limited, and Wipro Limited. History Systems Evolution, Inc. was incorporated in 1968.

SSEV News:

August 24 - Systems Evolution, Inc. Picks Up Hoss Motor Sports and Highline Hydrogen Hybrids From Failed Sympowerco Deal

Systems Evolution, Inc. (OTC: SSEV) announced that it has acquired Hoss Motor Sport, Inc. (HMSI) and Highline Hydrogen Hybrids, Inc. (HHHI).

SSEV's Chief Executive Officer Steven Humphries made the announcement today saying, "As a result of the termination of the Sympowerco, Inc. deal on Friday (8/21) we worked over the weekend we were able roll HMSI and HHHI into Systems Evolution."

In May of 2009 Steven Humphries entered into a Letter Of Intent to assign his interest in HMSI and HHHI to Sympowerco in exchange for 51% of SYMW's common stock. On July 26, 2009 the parties executed a Share Exchange Agreement. However, the transaction was never consummated and the agreement was terminated by all parties on Friday, August 21, 2009.

Humphries is the majority shareholder of SSEV. Under the terms of the SSEV purchase, the shareholders of HMSI and HHHI will take a combined 30% of SSEV.

Humphries added, "These are two great companies with tremendous potential and I am pleased that we were able to close the deal so quickly so that we can move forward with the development plans."

TURBINE TRUCK ENGINES INCORPORATED (OTCBB: TTEG)

"Up 156.25% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/TTEG.php

Turbine Truck Engines, Inc. is a technology company focused on the development, manufacture, and testing of its New Energy and Environmental Efficient Truck Engine intended for mass markets in the United States and abroad. This new engine design can utilize any known fuel source (gasoline, diesel, propane, natural gas, hydrogen, methanol, ethanol, or LPG) or fuel mixture, yet needs no coolant, lube, oil, filters, or pumps. The unique, lightweight turbine design has few moving parts, significantly reducing maintenance costs. The innovative cyclical detonation process produces a complete combustion of fuel-oxidation mixtures, resulting in greater fuel economy and few harmful exhaust emissions.

TTEG News:

August 24 - Strategic Alliance Between Turbine Truck Engines and AMEC Gains Momentum

In January 2009, Turbine Truck Engines, Inc. (OTCBB: TTEG) (TTE) and China's Aerospace Machinery and Electric Equipment Co. Ltd. (AMEC) entered into a strategic alliance, agreeing to collaborate on the engineering and technical development of the patented Detonation Cycle Gas Turbine Engine (DCGT). TTE also granted AMEC the exclusive license to commercialize the engine in China's automotive and busing markets when the design process is completed. TTE has learned that AMEC will have full access to the resources of Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd. (Aerospace Mitsubishi) in the engineering and development process.

Aerospace Mitsubishi is a joint venture (JV) between five companies from China, Japan, and Malaysia. AMEC's sister corporation, China Aerospace Automotive Industry Group (Aerospace Automotive), has a 30% stake in the JV, and Aerospace Automotive will be the channel through which AMEC will access Aerospace Mitsubishi resources. AMEC intends to develop 150 and 400 horsepower versions of the DCGT. Once developed, the engine will be manufactured in Aerospace Mitsubishi's state-of-the-art engine assembly plant. The plant is already producing 100,000 engines annually, and is expected to reach 15 million units annually when the facility is complete.

AMEC and Aerospace Automotive are wholly owned subsidiaries of China Aerospace Science and Industry Corp (CASIC). CASIC (www.casic.com.cn) is one of the largest state owned enterprises in China and employs more than 100,000 people, over 40% of which are technical and engineering personnel. CASIC is comprised of seven research institutions, two manufacturing bases, and several production enterprises. Of the 150 CASIC subsidiaries, six are publicly traded companies on the Hong Kong and China Exchanges. The corporation is responsible for the development of China's space program and is considered the most technically advanced enterprise in China.

Michael Rouse, President and CEO of TTE, is in China for high-level meetings with AMEC officials, and he observed, "AMEC's access to Aerospace Mitsubishi's resources will speed the process to which we are mutually committed, and I am excited about the implications of this development for all TTE and AMEC stakeholders."

MULTICELL TECHNOLOGIES INCORPORATED (OTCBB: MCET)

"Up 13.33% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/MCET.php

MultiCell Technologies, Inc., a biopharmaceutical company, develops and commercializes therapeutics based on a portfolio of patented drug development technology platforms. It involves in the research and development of degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The company’s therapeutic pipeline includes MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers; and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer. In addition, it has patented the ‘Sybiol’ synthetic bio-liver device to produce therapeutic proteins using BioFactories technology. The company was formerly known as Exten Ventures, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is based in Woonsocket, Rhode Island.

MCET News:

August 19 - MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines

MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program

MultiCell Technologies, Inc. (OTCBB: MCET) announced that it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.

The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."

The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.

IMAGEXPRES CORPORATION (OTC: IMJX)

"Up 150.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/IMJX.php 

ImageXpres is a digital imaging and printing company, headquartered in Rochester, NY. ImageXpres develops imaging systems solutions for commercial printing, consumer photo, health and business communications market segments. ImageXpres is currently manufacturing and marketing a family of self-service interactive digital kiosks, and LitePix Digital Displays, digital signs that provide unique advertising benefits for business owners.

IMJX News:

August 20 - ImageXpres "Digital" Checklist Assists & Documents Safer Surgery

Surg-i-Scan™ Checklist System Has Potential for Improved Patient Care, and Resultant Lower Insurance Costs to Hospitals

ImageXpres Corporation (OTC: IMJX) announced further details about its "digital" surgical safety checklist system, designed to re-enforce and document improved surgical safety protocols resulting from hospital use of surgical safety checklist boards now being sold to hospitals in the U.S.

ImageXpres is working closely with a number of medical surgical supply organizations in order to reach thousands of hospitals in a timely manner. The U.S. market is estimated at over $25 million annually, based upon the number of surgical operating suites, and could reach over $100 million annually by 2012.

John Zankowski, ImageXpres President and CEO, states, "The ImageXpres Surg-i-Scan Safety Checklist System, and accompanying checklist boards, signals the beginning of a new systems platform for digital interactive medical systems from ImageXpres. This is the first of several new software/hardware systems we have been developing for the past year, and one that should prove to be very beneficial to the medical surgical marketplace."

The analog, custom-designed Surg-i-Scan Safety Checklist boards are currently available for sale by ImageXpress. The ImageXpres Surg-i-Scan Safety Checklist digital system will be fully tested in hospital market trials before being generally available by fourth quarter.

The company will be announcing sales and distribution partnerships with companies already selling medical products to hospitals and operating rooms, which are looking for new products to distribute, in the U.S. and internationally.

Mr. Zankowski concludes, "This particular product is one that clearly can benefit every hospital and surgical suite no matter where they are located. The WHO study has documented the benefits to hospitals and patients, in terms of lowered deaths and lowered surgical procedural errors, thus saving lives and improving healthcare delivery. We are pleased to be a part of the WHO initiative, and we are working diligently to reach the thousands of hospitals and out-patient surgery centers who need our product."

"The Surg-i-Scan system incorporates several unique features, providing a comprehensive documenting of each surgical procedure performed at the hospital. We believe the benefits for the patient are the driving force for adoption of the checklist system by surgeons and hospitals. In addition, documentation of correct procedures by the operating team will lead to fewer lawsuits and lowered insurance premiums for doctors and medical centers, resulting in lower delivery costs and improved patient care."

POWER 3 MEDICAL PRODUCTS INCORPORATED (OTCBB: PWRM)

"Up 117.65% on Monday"

Detailed Quote: www.otcpicks.com/quotes/PWRM.php   

Power3 Medical Products Inc. is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

PWRM News:

August 20 - Power3 Medical Products, Inc. Files for Three Patents On Blood Test for Diagnosis of Early Stage Breast Cancer

Power3 Medical Products, Inc. (OTCBB: PWRM) announced that the company made significant advances in the technology for their BC-SeraPro serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

"Roughly 200,000 women in the US and 1.2 million women worldwide are diagnosed with breast cancer each year. In the US, roughly 40,000 women die of the disease because the cancer is caught too late. In fact, nearly 1/2 of all cancers are missed as false negatives, and 75% of the biopsies of suspected breast cancer performed are false positive and therefore could have been avoided if there was a more accurate test that could be made readily available," said Ira L. Goldknopf, Ph.D., president and chief scientific officer of Power3. "We now have made strides towards this goal through refinements in our blood test for early stage detection of breast cancer."

As disclosed in the patent applications, Power3 has identified a group of 22 blood serum proteins with abnormal concentrations in women with breast cancer. Using the company's BC-SeraPro platform, Power3 used these protein biomarkers to distinguish women with breast cancer from those with benign abnormal breast conditions and with normal breasts with sensitivities and specificities in the 80-90% range, in retrospective banked and prospective newly drawn samples from patients and controls. The biomarkers also distinguish between women with purely invasive primary breast cancer and women who also have ductal carcinoma in situ, which is often missed in mammograms. In addition, following the "Principals of Omic Medicine" that Dr. Goldknopf is promoting at international scientific meetings in the US and China, the company has disclosed methods for making biomarker specific antibodies for development of a user friendly commercial test for breast cancer.

"We are enthusiastic about the increased value of BC-SeraPro with these 3 exemplary patent filings. Although we are striving to commercialize with our tests, we also recognize that this work has potential to alleviate much suffering," commented Ms. Helen R. Park, CEO of Power3. "Thus we will be publishing our results in the near term."

HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)

"Up 29.41% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php 

In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.

HTDS News:

August 24 - Skymark Research Initiates Independent Research Coverage On Hard to Treat Diseases, Inc.

Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Hard to Treat Diseases, Inc. (OTC: HTDS). Skymark Research is currently offering a complimentary trial subscription. To view our research, go to www.skymarkresearch.com.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.